---
document_datetime: 2025-12-02 05:48:45
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/semglee.html
document_name: semglee.html
version: success
processing_time: 0.1106875
conversion_datetime: 2025-12-24 22:08:21.856171
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Semglee

[RSS](/en/individual-human-medicine.xml/66149)

##### Authorised

This medicine is authorised for use in the European Union

insulin glargine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Semglee](#news-on)
- [Related content](#related-content-631)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Semglee is a medicine used to treat diabetes in patients from 2 years of age. It contains the active substance insulin glargine.

Semglee is a 'biosimilar medicine'. This means that Semglee is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the EU.

Expand section

Collapse section

## How is Semglee used?

Semglee is available in pre-filled disposable pens and can only be obtained with a prescription. It is given by injection under the skin in the belly, the thigh, or the upper arm.

Semglee is used once a day at the same time each day. The dose of Semglee is worked out for each patient and depends on the patient's blood glucose (sugar) level and treatment with other insulin medicines. Semglee can also be used with diabetes medicines taken by mouth in patients who have type 2 diabetes.

Patients can inject themselves with Semglee if they have been trained appropriately.

For more information about using Semglee, see the package leaflet or contact your doctor or pharmacist.

## How does Semglee work?

Diabetes is a disease in which the level of blood sugar is high, either because the body cannot produce insulin (type 1 diabetes) or because the body does not make enough insulin or cannot use it effectively (type 2 diabetes). Semglee is a replacement insulin that acts in the same way as the body's own insulin and helps glucose enter cells from the blood. By controlling the level of blood glucose, the symptoms of diabetes are reduced and complications are avoided.

Insulin glargine, the active substance in Semglee, enters the bloodstream more slowly than human insulin after injection and so it works for longer.

## What benefits of Semglee have been shown in studies?

Extensive laboratory studies comparing Semglee with Lantus have shown that insulin glargine in Semglee is highly similar to that in Lantus in terms of chemical structure, purity and biological activity. Additional studies showed that Semglee is absorbed into the body in the same way as the reference medicine, Lantus, and could be considered to act similarly on blood glucose.

Because Semglee is a biosimilar medicine, studies on effectiveness and safety were not needed as these have been well established for insulin glargine. However, a supportive study in 558 patients with type 1 diabetes showed Semglee and Lantus had similar effects. Patients in the study had previously had their level of glycosylated haemoglobin (HbA1c), a substance which indicates how well blood glucose is controlled, brought under control with Lantus; continuing treatment with either Semglee or Lantus for 24 weeks indicated comparable control of HbA1c levels with both, the level changing by an average of 0.14% in patients given Semglee, and 0.11% in those given Lantus.

## What are the risks associated with Semglee?

The most common side effect with Semglee (which may affect more than 1 in 10 people) is hypoglycaemia (low blood glucose). For the full list of side effects and restrictions with Semglee, see the package leaflet.

## Why is Semglee authorised in the EU?

The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Semglee has been shown to have a comparable quality, safety and effectiveness to Lantus. Therefore, the Agency's view was that, as for Lantus, the benefit of Semglee outweighs the identified risk and it can be authorised in the EU.

## What measures are being taken to ensure the safe and effective use of Semglee?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Semglee have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Semglee is continuously monitored. Side effects reported with Semglee are carefully evaluated and any necessary action taken to protect patients.

## Other information about Semglee

Semglee received a marketing authorisation valid throughout the EU on 23 March 2018.

Semglee : EPAR - Medicine overview

Reference Number: EMA/57790/2018

English (EN) (105.93 KB - PDF)

**First published:** 23/05/2018

**Last updated:** 23/05/2018

[View](/en/documents/overview/semglee-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-315)

български (BG) (100.35 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/bg/documents/overview/semglee-epar-medicine-overview_bg.pdf)

español (ES) (75.1 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/es/documents/overview/semglee-epar-medicine-overview_es.pdf)

čeština (CS) (96.52 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/cs/documents/overview/semglee-epar-medicine-overview_cs.pdf)

dansk (DA) (73.36 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/da/documents/overview/semglee-epar-medicine-overview_da.pdf)

Deutsch (DE) (75.82 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/de/documents/overview/semglee-epar-medicine-overview_de.pdf)

eesti keel (ET) (73.04 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/et/documents/overview/semglee-epar-medicine-overview_et.pdf)

ελληνικά (EL) (110.6 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/el/documents/overview/semglee-epar-medicine-overview_el.pdf)

français (FR) (75.54 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/fr/documents/overview/semglee-epar-medicine-overview_fr.pdf)

hrvatski (HR) (94 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/hr/documents/overview/semglee-epar-medicine-overview_hr.pdf)

italiano (IT) (74.64 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/it/documents/overview/semglee-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (101.11 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/lv/documents/overview/semglee-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (94.57 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/lt/documents/overview/semglee-epar-medicine-overview_lt.pdf)

magyar (HU) (91.66 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/hu/documents/overview/semglee-epar-medicine-overview_hu.pdf)

Malti (MT) (98.07 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/mt/documents/overview/semglee-epar-medicine-overview_mt.pdf)

Nederlands (NL) (74.57 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/nl/documents/overview/semglee-epar-medicine-overview_nl.pdf)

polski (PL) (98.91 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/pl/documents/overview/semglee-epar-medicine-overview_pl.pdf)

português (PT) (75.22 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/pt/documents/overview/semglee-epar-medicine-overview_pt.pdf)

română (RO) (102.7 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/ro/documents/overview/semglee-epar-medicine-overview_ro.pdf)

slovenčina (SK) (97.65 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/sk/documents/overview/semglee-epar-medicine-overview_sk.pdf)

slovenščina (SL) (91.82 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/sl/documents/overview/semglee-epar-medicine-overview_sl.pdf)

Suomi (FI) (73.11 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/fi/documents/overview/semglee-epar-medicine-overview_fi.pdf)

svenska (SV) (75.32 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

23/05/2018

[View](/sv/documents/overview/semglee-epar-medicine-overview_sv.pdf)

Semglee : EPAR - Risk management plan summary

English (EN) (127.76 KB - PDF)

**First published:** 22/09/2023

[View](/en/documents/rmp-summary/semglee-epar-risk-management-plan-summary_en.pdf)

## Product information

Semglee : EPAR - Product Information

English (EN) (727.76 KB - PDF)

**First published:** 23/05/2018

**Last updated:** 01/12/2023

[View](/en/documents/product-information/semglee-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-873)

български (BG) (1001.08 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/bg/documents/product-information/semglee-epar-product-information_bg.pdf)

español (ES) (628.96 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/es/documents/product-information/semglee-epar-product-information_es.pdf)

čeština (CS) (742.64 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/cs/documents/product-information/semglee-epar-product-information_cs.pdf)

dansk (DA) (1.78 MB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/da/documents/product-information/semglee-epar-product-information_da.pdf)

Deutsch (DE) (805.14 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/de/documents/product-information/semglee-epar-product-information_de.pdf)

eesti keel (ET) (976.33 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/et/documents/product-information/semglee-epar-product-information_et.pdf)

ελληνικά (EL) (772.08 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/el/documents/product-information/semglee-epar-product-information_el.pdf)

français (FR) (1.78 MB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/fr/documents/product-information/semglee-epar-product-information_fr.pdf)

hrvatski (HR) (685.13 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/hr/documents/product-information/semglee-epar-product-information_hr.pdf)

íslenska (IS) (951.55 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/is/documents/product-information/semglee-epar-product-information_is.pdf)

italiano (IT) (632.09 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/it/documents/product-information/semglee-epar-product-information_it.pdf)

latviešu valoda (LV) (854.6 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/lv/documents/product-information/semglee-epar-product-information_lv.pdf)

lietuvių kalba (LT) (960.07 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/lt/documents/product-information/semglee-epar-product-information_lt.pdf)

magyar (HU) (706.37 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/hu/documents/product-information/semglee-epar-product-information_hu.pdf)

Malti (MT) (697.16 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/mt/documents/product-information/semglee-epar-product-information_mt.pdf)

Nederlands (NL) (884.98 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/nl/documents/product-information/semglee-epar-product-information_nl.pdf)

norsk (NO) (1.05 MB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/no/documents/product-information/semglee-epar-product-information_no.pdf)

polski (PL) (688.29 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/pl/documents/product-information/semglee-epar-product-information_pl.pdf)

português (PT) (878.23 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/pt/documents/product-information/semglee-epar-product-information_pt.pdf)

română (RO) (691.5 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/ro/documents/product-information/semglee-epar-product-information_ro.pdf)

slovenčina (SK) (852.04 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/sk/documents/product-information/semglee-epar-product-information_sk.pdf)

slovenščina (SL) (644.08 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/sl/documents/product-information/semglee-epar-product-information_sl.pdf)

Suomi (FI) (1.74 MB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/fi/documents/product-information/semglee-epar-product-information_fi.pdf)

svenska (SV) (847.94 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

01/12/2023

[View](/sv/documents/product-information/semglee-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0047 30/11/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Semglee : EPAR - All Authorised presentations

English (EN) (17.69 KB - PDF)

**First published:** 23/05/2018

**Last updated:** 04/06/2018

[View](/en/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-271)

български (BG) (88.61 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/bg/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_bg.pdf)

español (ES) (17.39 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/es/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_es.pdf)

čeština (CS) (56 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/cs/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (17.85 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/da/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (15.57 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/de/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (17.22 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/et/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (57.59 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/el/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_el.pdf)

français (FR) (33.45 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/fr/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (51.88 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/hr/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (15.86 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/is/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_is.pdf)

italiano (IT) (17.2 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/it/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (52.59 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/lv/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (52.46 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/lt/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (53.09 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/hu/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (53.7 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/mt/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (16.81 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/nl/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (17.75 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/no/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_no.pdf)

polski (PL) (54.82 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/pl/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_pl.pdf)

português (PT) (16.2 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/pt/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_pt.pdf)

română (RO) (86.91 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/ro/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (53.64 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/sk/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (52.4 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/sl/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (15.76 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/fi/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (16.85 KB - PDF)

**First published:**

23/05/2018

**Last updated:**

04/06/2018

[View](/sv/documents/all-authorised-presentations/semglee-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Semglee Active substance insulin glargine International non-proprietary name (INN) or common name insulin glargine Therapeutic area (MeSH) Diabetes Mellitus Anatomical therapeutic chemical (ATC) code A10AE04

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.

## Authorisation details

EMA product number EMEA/H/C/004280

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Biosimilar Collaborations Ireland Limited

Unit 35/36

Opinion adopted 25/01/2018 Marketing authorisation issued 23/03/2018 Revision 10

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Semglee : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (152.44 KB - PDF)

**First published:** 04/06/2018

**Last updated:** 01/12/2023

[View](/en/documents/procedural-steps-after/semglee-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Semglee-H-C-PSUSA-00001751-201904 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/56836/2020

English (EN) (189.32 KB - PDF)

**First published:** 16/03/2020

[View](/en/documents/scientific-conclusion/semglee-h-c-psusa-00001751-201904-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Semglee : EPAR - Public assessment report

Adopted

Reference Number: EMA/119474/2018

English (EN) (2.32 MB - PDF)

**First published:** 23/05/2018

**Last updated:** 23/05/2018

[View](/en/documents/assessment-report/semglee-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Semglee

Adopted

Reference Number: EMA/CHMP/13698/2018

English (EN) (84.02 KB - PDF)

**First published:** 26/01/2018

**Last updated:** 26/01/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-semglee_en.pdf)

#### News on Semglee

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-january-2018) 26/01/2018

#### Related content

- [Biosimilar medicines](/en/human-regulatory/overview/biosimilar-medicines)

#### Topics

- [Biologicals](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A44)
- [Biosimilars](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A45)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 22/09/2023

## Share this page

[Back to top](#main-content)